TI
ARCT icon

Turner Investments’s Arcturus Therapeutics ARCT Stock Holding History

Turner Investments’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-32,393
Closed -$1.28M – 251
2015
Q1 		$1.28M Buy
+32,393
New +$1.43M 0.23% 133

Other funds holding ARCT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Turner Investments's ARCT Position: Q2 2015 in Review

Turner Investments sold out of Arcturus Therapeutics (ARCT) in Q2 2015, closing a stake of 32,393 shares — an estimated $1.28M sold.

Turner Investments first reported a position in ARCT in Q1 2015 and held it in 1 quarter. The position peaked at $1.28M in Q1 2015. 32 funds tracked by Wall St. Rank hold ARCT as of Q2 2015.

  • Turner Investments reported no remaining Arcturus Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Turner Investments sold 32,393 Arcturus Therapeutics shares in Q2 2015, an estimated $1.28M.
  • Turner Investments first reported a position in Arcturus Therapeutics in Q1 2015 and held it in 1 quarter.
  • Turner Investments's Arcturus Therapeutics position peaked at $1.28M in Q1 2015.
  • 32 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2015.

Based on Turner Investments's 13F filing for Q2 2015, filed 12 Aug 2015.